UNSPSC 51314334: Chlorpheniramine/dextromethorphan/phenylephrine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314334 Chlorpheniramine/dextromethorphan/phenylephrine/phenylpropanolamine is a Commodity code that nominally designates a combination cold-and-allergy medication, but recent state and local procurement activity under this code shows a mismatch with the specific product — the opportunities tagged to it involve broad pharmaceutical procurement, naloxone supply, and multi-source generic medication programs rather than purchases of the named formulation itself. State and local health authorities, cooperative purchasing alliances, and county health departments issue solicitations under this code family for generic pharmaceuticals, over-the-counter products, and emergency medical supplies. The work involves establishing supply agreements with manufacturers and distributors, specifying product compliance with FDA requirements, Good Manufacturing Practices certification, and Drug Supply Chain Security Act adherence, along with requirements for insurance, E-Verify employment verification, and warehouse-and-delivery logistics.

Recent activity spans Florida, Texas, and Minnesota-led multi-state cooperative purchasing. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, requiring suppliers to maintain relationships with authorized wholesalers and submit pricing in multiple formats (flat price, net price, WAC-minus). Seminole County, Florida released an IFB (Solicitation No. IFB60459723LAS) in June 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2023, requiring 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the county health building. The Texas Health and Human Services Commission posted a Request for Information in April 2026 regarding direct-to-manufacturer prescription programs to explore vendor capabilities for a Therapeutic Pharmacy Initiative. The code shows modest recent activity concentrated in state health departments and county public health procurement rather than widespread jurisdictional adoption.